X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ASTRAZENECA PHARMA ELDER PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x -0.2 105.3 - View Chart
P/BV x 0.1 15.0 0.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ASTRAZENECA PHARMA
Mar-14
ELDER PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,285 29.6%   
Low Rs188634 29.7%   
Sales per share (Unadj.) Rs491.2189.6 259.1%  
Earnings per share (Unadj.) Rs-3.2-0.2 1,562.7%  
Cash flow per share (Unadj.) Rs14.43.8 374.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.568.6 548.5%  
Shares outstanding (eoy) m20.5425.00 82.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.65.1 11.4%   
Avg P/E ratio x-89.3-4,712.7 1.9%  
P/CF ratio (eoy) x19.7249.6 7.9%  
Price / Book Value ratio x0.814.0 5.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,83323,988 24.3%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,1791,605 135.8%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m10,0894,740 212.9%  
Other income Rs m25792 278.6%   
Total revenues Rs m10,3464,832 214.1%   
Gross profit Rs m-792-130 610.1%  
Depreciation Rs m361101 357.0%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,653-139 2,629.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713139 2,672.9%   
Tax Rs m1255 2,458.7%   
Profit after tax Rs m-65-5 1,283.9%  
Gross profit margin %-7.8-2.7 286.6%  
Effective tax rate %-3.4-3.7 93.5%   
Net profit margin %-0.6-0.1 603.2%  
BALANCE SHEET DATA
Current assets Rs m9,2402,726 338.9%   
Current liabilities Rs m9,9982,435 410.6%   
Net working cap to sales %-7.56.1 -122.2%  
Current ratio x0.91.1 82.5%  
Inventory Days Days4674 62.8%  
Debtors Days Days6041 147.1%  
Net fixed assets Rs m10,1241,035 977.9%   
Share capital Rs m20650 411.4%   
"Free" reserves Rs m5,582942 592.3%   
Net worth Rs m7,7341,716 450.7%   
Long term debt Rs m4,8890-   
Total assets Rs m22,8824,156 550.6%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.1 38.7%   
Return on assets %11.8-0.1 -9,602.2%  
Return on equity %-0.8-0.3 284.9%  
Return on capital %22.30-  
Exports to sales %3.05.7 53.3%   
Imports to sales %0.46.5 6.6%   
Exports (fob) Rs m307270 113.5%   
Imports (cif) Rs m43306 14.1%   
Fx inflow Rs m307375 81.8%   
Fx outflow Rs m125470 26.7%   
Net fx Rs m181-96 -189.7%   
CASH FLOW
From Operations Rs m11,754-8 -145,112.3%  
From Investments Rs m-561-146 384.7%  
From Financial Activity Rs m-6,762862 -784.2%  
Net Cashflow Rs m4,432709 625.5%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 16.8 15.7 107.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 9.1 396.7%  
Shareholders   16,479 12,856 128.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS